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Abstract: Transition-metal catalysis has changed the way in which chemical reactions can be accomplished.
While most metal-catalyzed reactions have been achieved in organic solvents, recent work has demonstrated
that many of these transformations can be made compatible with water. These discoveries have stimulated the
search for metal catalysts that are capable of achieving designed reactions in biological settings, and eventually
behave as non-natural enzymes working in native cellular environments. Although this new field of research is
still taking its first steps, there is a growing number of publications in the area, and one can predict that it will
steadily grow in the years to come. Here we will briefly review some of the main contributions in the area. The
contents have been organized according to the type of transformation and transition metal catalysts involved in
the process.
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to biological settings is extremely chal-
lenging due to the aqueous environment,
and to the presence of a high concentration
of biomolecules such as thiols or amines
which can poison the metal and kill its
catalytic activity. In the case of reactions
in living cells, additional issues such as
toxicity of the metals and cellular transport
must also be taken into account. Despite
these challenges, there have been an in-
creasing number of reports on the use of
metal-based catalysts in aqueous buffers,
biological media and even in vivo settings.
The viability of promoting non-natural
transformations in such environments can
have profound implications in biological
and medicinal research, both in terms of
advancing basic knowledge as well as of
discovering new therapeutic or diagnosis
strategies.[1–4]
A key development that triggered this
field of research at the boundary between
metal catalysis and chemical biology was
the discovery of the Copper-Catalyzed
Azide-Alkyne Cycloaddition (CuAAC)
by the groups of Sharpless and Meldal.[5,6]
The water compatibility and excellent or-
thogonality of this annulation prompted
the development of many applications in
biological chemistry, many related with
designed modification of sugars[7–9] and
proteins on cellular surfaces.[10] This an-
nulation, together with the Staudinger re-
action, were the first to be included in the
new research area coined as Bioorthogonal
Chemistry.[11,12]
After these developments, there have
been many attempts to discover other or-
thogonal and biocompatible transition-
metal promoted reactions, however the
success has been fairly limited. Davis, Lin
and others have demonstrated the viabil-
ity of using Pd-catalyzed coupling reac-
tions for protein modification in biological
compatible media, and even on the surface
of bacteria.[13–15] Moving this chemistry to
mammalian living cells has been specially
challenging, owing to the intermolecular
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Annulation of exogenous small mol-
ecules. Promoting the CuAAC of small
molecules inside living environments is es-
pecially challenging, owing to the entropic
difficulties associated with the bimolecular
process.
The first example of the use of a copper
complex to promote a click-type annulation
of small molecules inside living cells was
reported by Taran et al. in 2014. Following
the copper-chelate concept devised by A.
Ting,[10] they designed azides bearing cop-
per-chelating bis(triazole) moieties, and
demonstrated that they present good kinet-
ics in the annulation with alkynes (Scheme
1a). This allowed reactions to be carried out
under diluted conditions in complex aque-
ous media, and even inside HUH-7 cells.[33]
In 2016, the group of Zimmerman
demonstrated that Cu-containing organic
nanoparticles (Cu-MONPs) are able to
promote a CuAAC of 3-azido-7-hydroxy-
coumarin and p-ethynylanisole to gener-
ate the fluorescent triazole product 1 in-
side bacteria or living mammalian cells
(Scheme 1b). The reaction required the use
of a large amount of reducing ascorbate.
The exact Cu(i) species promoting the
reaction is not clear. With these heteroge-
neous copper catalysts they were also able
to synthesize bioactive triazole products
inside cells; products that otherwise might
be difficult to deliver.[34]
The group of M. Bradley and cowork-
ers explored the use of polymeric sup-
ported copper nanoparticles (CuNPs) as
catalytic nanoreactors. TheseCuNPswere
able to promote a CuAAC of small mol-
ecule azides and alkynes in the presence
of living cells. The reaction was applied to
the synthesis of a triazole cytotoxic anti-
out by D.A. Tirrell and co-workers who re-
ported several Cu(ii) and Cu(i) complexes
able to promote the covalent labelling of
cell surface proteins of E. coli equipped
with azide-modified amino acids. They
also showed that the metabolic incorpora-
tion of a homopropargylglycine residue
provides for a subsequent copper-promot-
ed annulation with 3-azido-7-hydroxy-
coumarin, which allowed to visualize and
monitor the proteins in fixed mammalian
cells.[27–29]
The group of P. R. Chen has used the
CuAAC reaction for the modification
of a periplasmic pH-responsive acid-
chaperone HdeA in E. coli. with a naph-
thalimide dye (4-N,N-dimethylamino-1,8-
naphthalimide).[30] They later showed that
with appropriate copper ligands it is also
possible to achieve the reaction in the cy-
toplasm of the bacteria (Fig. 1).[31]
A. Ting and coworkers reported an el-
egant and efficient version of the CuAAC
relying on a favored interaction of the
azide with the copper complex owing to
the presence of a neighboring pyridine
capable of chelating the Cu(i) ion. The
strategy not only allows to accelerate the
reaction, but also to reduce the toxicity of
Cu(i). The efficiency of this approach was
demonstrated with its application in the
modification of proteins on the surface of
human embryonic kidney (HEK) cells.[10]
More recently, C. Cai and co-work-
ers demonstrated that linking copper
tris(triazole) ligands to cell penetrating
peptides enables protein modification in-
side cells by using the CuAAC. However,
the efficiency of the reaction is hampered
by the presence ofmillimolar concentration
of glutathione in the cytosol of the cells.[32]
nature of the reaction, and because the pal-
ladium reagents can be readily deactivated
in presence of a relatively high concentra-
tion of biomolecules such as thiols and
amines. Nevertheless, Unciti-Bruceta and
Bradley have reported the use of supported
Pd(0) nanoparticles to promote Suzuki-
Miyaura cross coupling reactions in living
cells.[16] These authors also demonstrated
that the palladium nanoparticles can be
used to remove allylcarbamate groups in
different type of substrates. The group of P.
R. Chen has also employed commercially
available Pd(ii) and Pd(0) complexes for
the uncaging of propargylcarbamate pro-
tected amines groups of proteins involved
in the cell metabolism,[17] and more recent-
ly,Weisleder and coworkers have also used
nanoprotected forms of palladium com-
plexes to achieve similar deprotection re-
actions within living mammalian cells.[18]
While all these examples involve the use
of palladium, a seminal report in this topic
was published more than ten years ago by
E. Meggers and coworkers and dealt with
related uncaging reactions promoted by
Ru(ii) complexes.[19]
In this short review, we will make a
compilation of some of the more remark-
able results in this emerging research
field devoted to the development of abi-
otic metal-promoted processes in living
environments. The contents of the review
have been organized according to the type
of chemical transformation that can be
achieved, and the main metals that have
been used.[20–25] Of course, we do not in-
tend to be comprehensive, and therefore
we apologize for not citing all the refer-




Although annulations do not appear to
be the simplest reactions to be achievable
in complex aqueous media, the ground-
breaking discovery of the bioorthogonal
CuAAC triggered a substantial research
effort in the area.
2.1.1 Copper
Modification of proteins. After the dis-
covery that copper (i) salts or complexes
can catalyze the annulation between azides
and alkynes in water, there have been
many reports trying to exploit this reac-
tion (CuAAC) in bio-related research.[5,6]
However, the well-known toxicity of cop-
per and the need to use non-innocent re-
ducing agents like ascorbate for the in situ
generation of Cu(i), has limited their use in
living environments.[26]
Pioneering work on the use of the
CuAAC in biological settings was carried
Fig. 1. Protein modifications with CuAAC reactions. Representation of a CuAAC modification of
HdeA protein in E coli.[31]
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2.2 Couplings
Transition-metal catalyzed cross-cou-
pling reactions can be considered among
the more relevant transformations in the
field of synthetic and medicinal chemistry.
Being able to achieve these bond-forming
reactions in aqueousmedia and bio-relevant
environments would also be of prime rel-
evance. Despite the enormous difficulties
associated with this challenge owing to the
common requirement of organic solvents or
additives to obtain good results, and the bi-
molecular nature of the processes, a number
of examples have demonstrated the viability
of achieving palladium-catalyzed Suzuki-
Miyaura, Sonogashira or Heck reactions in
complex aqueous media.
2.2.1 Palladium
Suzuki-Miyaura couplings. Work on
the topic has been pioneered by the group
of B. G. Davis, who demonstrated that it is
possible to achieve Suzuki-Miyaura cross-
couplings on suitably modified proteins
was not yet demonstrated, as it would re-
quire to increase the reaction rate so that it
can be achieved with micromolar amounts
of the reactants.
2.1.3 Iridium and Rhodium
Very recently, there have been several
reports on the application of other late
transition metals to promote azide–alkyne
annulations, some of which tolerate oxy-
gen and water. In 2014, Jia and coworkers
reported the use of Ir(cod)Cl
2
to promote
the annulation of thioalkynes, albeit most
of the examples were described in organic
solvents.[40] More recently, Huang and
coworkers reported a rhodium-catalyzed
azide–alkyne cycloaddition of internal yn-
amides, and demonstrated that the reaction
is also operative in water.[41]
The use of Rh and Ir in living settings
has not yet been explored, except for a re-
dox reaction promoted by an iridium re-
agent that is taking place in cellular con-
texts (see Section 4.2).
cancer agent derived from Combretastatin
(2) (Scheme 1c). However the reaction was
confirmed to take place in the extracellular
medium, rather than inside cells.[35]
Later on, in 2018, the group of J. L.
Mascareñas demonstrated that water-sol-
uble copper(i) complexes featuring de-
signed ligands can tune the cell uptake and
reactivity of Cu(i) complexes and thereby
promote intracellular CuAAC annulations
of small, abiotic and freely diffusible mol-
ecules. In particular, they demonstrated the
intracellular reaction between anthracenyl
azide 3 and propargyl alcohol in presence
of a predefinedCu(i) complex [Cu(BTTE)]
(PF
6
), and in absence of ligands or ascor-
bate, to yield the fluorescent adduct 4
(Scheme 1d).[36]
These results suggest that playing
with ligands, it might be possible to de-
sign Cu(i) complexes with low toxicity,
good transport properties and an appro-
priate balance between reactivity and sta-
bility. It might even be possible to target
different cells, or subcellular organelles,
which could open new avenues on the
applicability of the CuAAC in living set-
tings and on its potential translation to
biomedicine. One important advantage of
the CuAAC reaction with respect to other
metal-promoted processes is related to the
good rates that can be achieved, which al-
lows to use very low concentrations of the
substrates. The main disadvantages are
still associated to the oxidative lability
and cytotoxicity of Cu(i) complexes, as
well as the difficulties in controlling the
bioorthogonality.
2.1.2 Ruthenium
Several catalytic annulations of al-
kynes mediated by ruthenium complexes
have been reported.[37] In 2005 Fokin and
Jia described a ruthenium version of the
CuAAC, with the important difference that
the reaction can be achieved with disub-
stituted alkynes, while the CuAAC only
works efficiently with terminal alkynes.[38]
However, the reaction was described only
in organic solvents and provides a mix-
ture of regioisomeric adducts. Recently,
the group of J. L. Mascareñas developed
a water-compatible Ru-promoted annu-
lation involving azides and thioalkynes
(RuAtAC).[39] The reaction was better
promoted by the complex [RuCp*(COD)
Cl] (A) at room temperature, and is highly
bioorthogonal, as it can be achieved in
water, in phosphate-buffered saline (PBS)
solutions containing biomolecules (gluta-
thione, amino acids, peptides), in complex
biological media such as cell lysates and
fetal bovine serum, and even in the pres-
ence of living bacteria (Scheme 2).[39]
While these results are very appealing,
and ruthenium is less toxic than copper, the
application of RuAtAC in living settings
Scheme 1. CuAAC reactions of small molecules achieved in cellular settings. a) Chelating azides
used by Taran et al.;[33]b) Zimmerman et al. used polymeric copper nanoparticles (Cu-MONPs);[34]
c) Bradley et al. employing polystyrene supported CuNPs[35] and d) Mascareñas et al. described
discrete Cu(i) complexes for the CuAAC in living cells.[36]
Scheme 2. Ruthenium-catalyzed azide-thioalkyne cycloadditions in aqueous media (RuAtAC).[39]
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2.2.2 Gold
Amidations. Tanaka et al. reported in
2017 an Au(iii) complex capable of pro-
moting an amidation reaction even in liv-
ing mice. This Au(iii) conjugate 6 pos-
sesses a 7-diethylaminocoumarin linked to
a water-compatible cyclometalated Au(iii)
complex via a short PEG linker (Scheme
5). The authors indicate that this compound
is able to bind to specific sugars in differ-
ent tissues and claimed that the resulting
hybrids are capable of promoting an am-
ide bond formation between fluorescent
propargyl ester probes and nearby surface-
protein amines (e.g. lysine side chains).[48]
2.3 Cyclizations
Cyclization reactions allow cyclic
products to be built from acyclic precur-
sors, and usually involve the formation of
at least one new bond. Despite their con-
structive power, metal-promoted, aqueous
to the use of Sonogashira cross-coupling
reactions in aqueous solvents. They even
demonstrated the viability of using the
reaction in E. coli to modify an overex-
pressed ubiquitin protein which incorpo-
rates an homopropargylglycine residue.[14]
They have also expanded the application of
the cross-coupling reaction to the surface
of mammalian cells, being able to modify
alkynyl-equipped proteins bound to the
cellular membrane.[46,47]
in biological compatible settings, using
Pd(OAc)
2
together with a 2-amino-4,6-
dihydroxypyrimidine ligand (L) (Scheme
3).[42] Indeed, they were even able to pro-
mote such a carbon–carbon bond forming
reaction on the cell-surface ofE. coli, using
genetically ‘tagged’ aryl halide-containing
porin channels.[13] Reportedly, the major
drawbacks of the reaction are related to its
incompatibility with thiols, such as that of
glutathione.
While it is clear that achieving pal-
ladium-promoted Suzuki-Miyaura cross
couplings inside living mammalian cells
is far from easy, in 2011 the group of
Bradley[16] indicated that Pd(0) nanopar-
ticles supported on polystyrene micro-
spheres (Pd0-MS) can promote the cou-
pling of the designed substrates inside
HeLa cells (Scheme 4a), albeit the cells
were fixed before analyzing the results.
The phosphonium moiety in the product
allows for its mitochondria localization.[16]
Later on, they also explored an in cellulo
dual drug synthesis promoted by these
small Pd(0) microspheres. Specifically,
their Pd(0) nanoparticles promoted the
synthesis of the anticancer agent 5 via
Suzuki–Miyaura cross-coupling of two
benign precursors (Scheme 4b), and the si-
multaneous depropargylation (see Section
3.2.1) of a fluorouracil derivative.[43,44]
A interesting recent article by Qu and
coworkers described the use of light-acti-
vatable heterogeneous palladium species
for promoting bioorthogonal coupling
reactions in living cells.[45] The authors
modified macroporous silica-Pd(0) with
supramolecular complexes of azobenzene
(Azo) and β-cyclodextrin (CD), so that up-
on light irradiation it is possible to modu-
late such interactions and hence the access
of substrates to catalytic sites.[45]
These advances in the implementa-
tion of Suzuki-Miyaura cross couplings
have been essentially restricted to the
use of Pd(0) nanostructured species as
catalytic materials. The development of
discrete palladium catalysts capable of
achieving intracellular carbon–carbon
bond forming reactions remains to be
demonstrated.
Sonogashira couplings. Q. Lin and
co-workers made important contributions
Scheme 3. Modification of the bacterial protein SBL by Suzuki-Miyaura cross coupling. 18F la-
belling of bacterial protein SBL through C–C bond formation employing Pd(OAc)2 as palladium
source and the ancillary ligand L1, published by Davis and coworker.[42]
Scheme 4. Suzuki-Miyaura cross coupling reactions claimed to occur in HeLa cells. a)
Fluorescent probe generated by Suzuki-Miyaura cross coupling promoted by Pd(0)-microspheres.
The presence of the triphenylphosphonium group allowed accumulation in the mitochondria[16]
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compatible bioorthogonal cyclizations
have been rarely pursued.
2.3.1 Gold
The development of aqueous compati-
ble transformations promoted by gold com-
plexes is still in a very early stage. Goldwas
considered an inert element for many years,
however, in the last two decades there has
been a boost in the development of gold-
catalyzed reactions.[49–57] The reactivity of
Au(i) and Au(iii) complexes is associated
to their carbophilicity, in particular, to the
ability of these metals to coordinate and
activate unsaturated bonds.While the com-
patibility of this reactivity with water and
especially with the presence of biological
media was dubious, in 2010, Kim and co-
workers reported a gold reactive alkynyl
probe that is able to detect the presence of
Au(iii) salts in cells, by taking advantage
of the reactivity promoted by the metal.
Specifically, the authors described a gold-
promoted cyclization that provides fluores-
cent coumarin products.[58] Later, in 2014,
Ahn and coworkers reported another strat-
egy for sensing gold salts in cells based on
gold(iii)-promoted oxa-cyclizations, with
concomitant ring opening of a rhodamine-
lactam ring.[59]
Just recently, the group of J. L.
Mascareñas reported a series of Au(i)
phosphine complexes capable of promot-
ing the cyclization of a designed procou-
marin 7 to give the corresponding cou-
marin product 8, even in cellular contexts
(Scheme 6). The authors were also able to
demonstrate the viability of combining the
gold-promoted reaction with a deallylation
process promoted by ruthenium (9 to 10),
so that both reactions could be carried out
inside living HeLa cells in a fully bioor-
thogonal and mutually orthogonal manner
(Scheme 6).[60]
2.3.2 Palladium (Heck)
To the best of our knowledge, the only
example of a palladium-mediated cycli-
zation carried out in the presence of liv-
ing cells has been recently reported by
Weissleder and coworkers.[18] The authors
demonstrated the possibility of assembling
a coumarin fluorophore (7-diethylamino-
coumarin) from its non-fluorescent pre-
cursor in HT1080 cells, via intramolecular






a polymeric formulation based on poly-
lactic acid-co-glycolic acid (PLGA) and
polyethylene glycol–poly lactic acid-co-
glycolic acid (PLGA-PEG, Scheme 7).[18]
2.3.3 Ruthenium (Ring-closing
Metathesis)
The ring-closing metathesis reaction is
a well-known, extremely effective manner
of building cyclic alkene products from
dialkenyl acyclic precursors. T. Ward and
coworkers have recently demonstrated the
viability of achieving such reactions in the
periplasm of E. coli using artificial metal-
loenzymes equipped with the required ru-
thenium catalysts. These metalloenzymes
were built using their previously devel-
oped biotin-streptavidine (biot-Sav) strat-
egy, based on equipping the biotin moiety
with different types of metal complexes,
so that upon assembling with streptavidine
they generate such metalloproteins.[61] To
promote the ring-closing metathesis, they
built ruthenium-based metalloenzymes
from the corresponding biotin conjugates
(biot-Ru, Fig. 2).[62]
The above examples demonstrate the
viability of achieving bond-forming re-
actions in complex aqueous media, and
in some cases even in living settings.
Therefore, the design of adequate ligands
for Cu(i) ions has allowed CuAAC annu-
lations of small abiotic substrates to be
performed inside living cells. The toxicity
of copper has promoted the development
of related annulations promoted by other
metals. While recent publications demon-
strate the viability of using ruthenium, rho-
dium or iridium catalysis for azide–alkyne
annulations in aqueousmedia, applications
in living cells remain to be demonstrated.
Palladium-promoted cross-coupling re-
actions have been successfully achieved in
cells, but they seem to require nanostruc-
tured materials, or protected forms of the
palladium. However, some isolated ex-
amples indicate that discrete Pd complexes
can promote the covalent modification of
proteins in biological compatible media
and, in some cases, in the surface of bacte-
Scheme 6. Concurrent Au(i) and Ru(iv) catalysis inside HeLa cells. Schematic representation of the
ruthenium and the gold-intracellular transformations mediated reactions, each one of the obtained
products possess different emissive properties that can therefore be readily monitored.[60]
Scheme 7. Pd cata-
lyst encapsulation
and Heck Pd cycliza-
tion. Representation
of the encapsulation






Fig. 2. Biot-Ru-Sav metalloenzyme at the bacterial periplasm. a) Streptavidin is secreted to the
periplasm by fusion to an N-terminal signal peptide from the outer membrane protein A (OmpA);
b) the biotinylated organoruthenium catalyst binds to the Sav forming the biot-Ru–Sav; c)
Catalytic bio-orthogonal metathesis reaction promoted by the biot-Ru–Sav metalloenzyme at the
periplasm of E. Coli. Adapted with permission from ref. [62], copyright 2017 Nature Publishing
Group.
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ing the complex [RuCp*(η6-pyrene)]PF
6
(Fig. 4,B), which can be activated (detach-
ment of the pyrene ligand) by irradiation
with UV light (λ = 330 nm).[65]
As already commented, these uncag-
ing strategies employing RuCp*(COD)Cl
(A) required the use of PhSH as addi-
tive to favor the deallylation process; a
compound that is toxic to cells. In 2014
Volker and Meggers demonstrated that
using Kitamura’s type of ruthenium cata-
lysts, which are equipped with quinoline
ligands,[66,67] the addition of this exter-
nal nucleophilic thiol is not needed; the
glutathione present in the cells is strong
enough to ensure the turnover in the cata-
lytic process. Indeed, they demonstrated
that with this type of ruthenium complex
the in vitro turnover number (TON) of the
reaction is considerably higher than that
obtained with the original complex A.
This activity can be even further tuned by
changing the substitution in the position 4
of the quinoline ligand (Fig. 4, complexes
C–E).[68]
In 2016, J. L. Mascareñas and cowork-
ers demonstrated that it is possible to engi-
neer the ligands of Kitamura’s ruthenium
complexes to introduce different cellular
targeting groups (Fig. 4, complexes F–H).
In particular, they found that using a triphe-
nylphosphonium derivative the ruthenium
complex accumulates in the mitochondria
of living cells, where it is still able to pro-
mote the uncaging of the alloc-protected
rhodamine.[69] Importantly, the ruthenium
complex G was not only tested towards
standard fluorogenic probes, but also with
when protected as alloc derivatives, are
unable to bind DNA but can readily inter-
nalize into cells. If these cells were previ-
ously treated with the ruthenium complex
A and a small amount of thiophenol, the
probes are rapidly converted into the active
DNA binders, a process that can be readily
monitored by fluorescence microscopy.[64]
In 2012, Meggers and coworkers car-
ried out a similar deprotection reaction us-
ria. Preliminary results indicate the viabili-
ty of achieving other types of bond-forming
reactions, especially cyclization processes,
using gold or ruthenium catalysts.
While much remains to be learned and
achieved, these results provide a solid proof
of concept, and therefore, in the coming
years, we should expect both the discov-
ery of new reactions, and the development
of important biological applications either
related with the controlled generation of
drugs or with the building of primitive,
non-natural metabolisms.
3. Bond-cleaving Reactions
3.1 Removal of Allyl/Alloc Groups
3.1.1 Ruthenium
In 2006, the group of E. Meggers pub-
lished a pioneering work on the use of
metal catalysis in living cells. Specifically,
they reported the removal of allylcar-
bamate-protecting groups in HeLa cells
promoted by ruthenium (ii) complexes.[19]
They could monitor the reaction in the cel-
lular settings, because the substrate, a bis-
allylcarbamate derivative of Rhodamine
110 is essentially non fluorescent, but pro-
vides green-emitting Rhodamine when de-
protected by the action [RuCp*(COD)Cl]
(A) and thiophenol (Fig. 3).
The group of J. L. Mascareñas re-
ported an application of this ruthenium-
based strategy for the controlled activation
of DNA binders like 4',6-diamidine-2'-
phenylindole (DAPI), ethidium bromide
(EtBr) and bisbenzamidines[63] inside liv-
ing mammalian cells. These compounds,
Fig. 4. Structure of several ruthenium complexes used as catalysts in biological settings. a) A[18]and
B;[65]b) Kitamura’s derived Ru(iv) catalysts C–E employed by Meggers et al.;[68] c) catalysts F–H synthe-
tized by Mascareñas et al., in the study of mitochondrial specific catalysis[69] and d) second generation
of quinoline derived Ru(iv) catalyst (I) reported by Meggers et al.[70]
Fig. 3. Ruthenium-promoted deprotection. a) Representation of the uncaging of Rhodamine-
alloc promoted by A and b) imaging of HeLa cells: i) before the addition of the Ru catalyst to cells
preincubated with Rhodamine-alloc, and PhSH and ii) 15 minutes after the addition of ruthenium
complex A. Adapted by permission from ref. [19]. Copyright 2006, Wiley-VCH.
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caging reaction involving internal propar-
gylic thioethers (Scheme 9). In this report
the uncaging is promoted by Pd(COD)Cl
2
and the cleavage was performed in cell
culture media. They even demonstrated
that the strategy can be used for a con-
trolled release of doxorubicine in the
extracellular media; a compound which
after internalization induces the death of
the cell.[73]
Mascareñas and coworkers have also
shown that the Pd-phosphine complexes
used in the case of the deallylation reac-
tions, can also be effective in the uncaging
of propargyl protecting groups in probes
11 and 12 (Fig. 6). Furthermore, prelimi-
nary data suggested that there is some turn-
over in the reactions that take place inside
living HeLa cells.[71]
by palladium complexes likely involves
Pd(0) reagents, the depropargylation
mechanism might proceed via Pd(ii/iv)
or Pd(0/ii) cycles.[17] The Pd-promoted
uncaging reaction can be readily moni-
tored using a di-propargylcarbamate-rho-
damine probe (11, Scheme 8b), thanks to
the green light emission of the released
rhodamine product.
In a more recent publication about
bioorthogonal reactions promoted by
palladium catalysts, M. Bradley et al.,
presented homogeneous tagged carbene-
based Pd(ii) catalysts conjugated to a
cell-penetrating peptide which are able to
promote the deprotection of the rhodamine
probe 11 inside PC-3 cells.[72]
G. Bernardes and coworkers have re-
cently reported a palladium-promoted un-
the caged protonophore 1-(allyloxy)-2,4-
dinitrobenzene. The in situ uncaging gen-
erates 2,4-dinitrophenol that works as a
very efficient uncoupler of the mitochon-
drial membrane potential.[69]
In 2017, T. Volker and E. Meggers
described a new generation of quinoline
derived Ru(iv) complexes (Fig. 4, I) that
present improved stability and excellent
catalytic potential under bio-relevant con-
ditions, even in blood serum.[70]
All these data confirm that appropri-
ately designed Ru complexes are able to
achieve very interesting deallylation reac-
tions in biologically relevant aqueous mix-
tures and even in living cells, in a bioor-
thogonal manner and without generating
major cytotoxicity.
3.1.2 Palladium
Bradley and Unciti-Broceta have pio-
neered the use of palladium nanostructured
materials to promote chemical transforma-
tions in living settings, as was already com-
mented above (see Section 2.2.1). These
Pd(0)-microspheres were demonstrated
to be highly effective for the uncaging of
rhodamine-alloc probes even in cellular
systems.[16]
In 2017 R. Weissleder and co-workers
reported another example of the applicabil-
ity of palladium catalysts for deallylation
reactions in living settings.[18] A polymer-
embedded palladium complex is very effec-
tive in the deprotection reaction of rhoda-
mine-alloc probes as well as in the uncag-
ing of a Doxorubicin-alloc prodrug. These
experiments were even carried out in vivo
using mice, with very promising results.[18]
More recently, the group of
Mascareñas demonstrated that discrete
Pd(ii) complexes with designed phos-
phine ligands present the right balance
of reactivity and stability to achieve
deallylation reactions in living Hela and
Vero cells. Adequate modification of the
phosphine ligands permitted a preferen-
tial accumulation of the complexes in the
mitochondria, which as in the case of the
ruthenium, allows for site specific trans-
formations (Fig. 5).[71]
3.2 Removal of Propargyl Groups
3.2.1 Palladium
Several groups have shown that pal-
ladium can also be used to uncage propar-
gyl-protected functional groups. In 2014,
the group of P. R. Chen reported the use of
discrete Pd(ii) catalysts to achieve chemi-
cal protein activations in living cells, us-
ing a depropargylation reaction of pro-
tected lysines (Scheme 8a). This uncaging
strategy was used for the chemical rescue
of a non-overexpressed bacterial enzyme
phosphothreonine lyase (OspF) within







atalyst.[17] While removal of allyl groups
Fig. 5. Discrete Pd(ii) complexes in living cells. a) Representation of the uncaging reaction; b) Co-
localization of the Pd catalyst with TMRE in HeLa cells, observed 2 h after incubation with the
palladium complex: i) Blue light emission of catalyst; ii) red light emission from the mitochondrial
dye TMRE, iii) merged image of i) and ii). c) Pd-promoted reaction: i) blue light emission of the
Pd catalyst; ii) green light emission from released Rhodamine 110, iii) merged image of i) and ii).
Adapted with permission from ref. [71]. Copyright 2018 American Chemical Society.
Scheme 8. Propargyl uncaging in living cells. Representation of the a) activation of the non-
overexpressed bacterial enzyme phosphothreonine lyase (OspF), and b) uncaging of a) the proc-
caged probe 11 [17]
Scheme 9. A thioether-directed palladium-cleavable linker. Representation of the decaging of bi-
functional propargyl carbamates in cultures of cancer cells.[73]
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face, and the nucleophilic cooperative ac-
tion of gold-tethered glutathione (GSH,
Fig. 7).[75]
3.3 Uncaging of Allene-protected
Precursors
Using commercially available Pd










among others, Chen and
coworkers have also described the re-
lease of tyrosine-dependent proteins in
living cells using genetically encoded
proteins containing allene-protected ty-
rosines.[76]
In summary, an already important
number of examples demonstrate the
viability of achieving metal-promoted
uncaging reactions involving bond-
cleavage processes in biological media
and living settings. The reactions have
been used for the release of fluorogenic
probes and the activation of prodrugs or
different type of biomolecules, includ-
ing proteins. Some of the reactions have
been even targeted to specific cells or to




The group of Sadler has extensively
demonstrated the viability of using organo-
metallic Ru complexes as catalytic drugs
to tune the redox potential of cells, as they
interfere with the redox balance controlled
by GSH and NAD/NADH.[77–79] Almost
all of these ruthenium (and some osmium)
complexeswork on endogenous rather than
exogenous substrates, and therefore are not
specifically discussed in this review. In a
recent publication they have shown that
novel organo-osmium catalysts improved
our knowledge, there is only one exam-
ple in the literature. A. Unciti-Broceta
et al. described the preparation of gold
nanoparticles (AuNPs, 30 nm) supported
within a PEG-grafted low-cross-linked
polystyrene matrix (75 mm), and their
use for promoting the removal of propar-
gyl protecting groups of rhodamine alloc
11.[75] ThisAu-resin was also successfully
tested in cell culture media, and even in
vivo, using zebrafish as animal model.
The deprotection reaction involves the
activation of the alkyne by the gold sur-
The group of P. R. Chen explored the
modification of cell membranes by induc-
ing cellular aggregation processes con-
trolled by a palladium-promoted decaging
of a propargyl protected form of neuramic
acid (Neu5Proc). The best reaction results
were obtained using Pd(0)-nanoparticles
instead of discrete commercially available
Pd sources used in previous reports by the
same group.[15]
In line with their previous work,
Bradley and coworkers investigated the
use of microspheres containing Pd(0)
nanoparticles for the uncaging of a
propargyloxy-protected probe in zebra-
fish. Inserting the palladium-micro-
spheres in their yolk-sac, the authors were
able to observe an increase in the fluo-
rescence after incubation with the caged
fluorogenic probe 11 due to the release of
the fluorescent product.[74] These Pd(0)-
nanoparticles (9.2 ± 1.5 nm) can also be
supported on a modular polymer (9.9
×7.5 mm) and the constructs are capable
of inducing a depropargylation in cell
culture media.[44] The introduction of fur-
ther modifications onto the Pd(0) micro-
spheres with the cyclic peptide cRGDfE
allowed an specific uptake by brain can-
cer cells, the uncaging of 5FU-proc and
the generation of 5FU (Scheme 10).[43]
3.2.2 Gold
The application of gold complexes
to promote the uncaging of propargylic
probes is very recent, and to the best of
Fig. 6. Pd(ii) phosphine-derived complexes for in cellulo propargyl uncaging. a) Schematic repre-
sentation of the uncaging reaction of the propargylated probe 12 and b) imaging of the reaction
in Vero cells. First row – red channel; second row – brightfield and red channels merged (i: mock,
ii: L = L2; iii: L = L3 and iv: L = L4); c) Imaging of the uncaging of 11 in Hela cells. i) blue emis-
sion arising from the pyrene groups of Pd ligand L5 (blue channel), ii) green emission arising from
the released Rhodamine 110 (green channel); iii) merged image of i) and ii); iv) merged imaging of
the brightfield and the green channel and v) merged of the brightfield with the green and the blue
channels. Adapted with permission from ref. [71]. Copyright 2018 American Chemical Society.
Scheme 10. Pd-
catalyzed release







Fig. 7. GSH role on the Au-promoted alkynyl-ester activation. Reproduced by permission from ref.
[75]. Copyright 2017. Wiley-VCH.
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that demonstrate the feasibility of using
different types of metals for such an en-
deavor. While the field is in its infancy,
there is an constant growth in publica-
tions reporting new types of transfor-
mations in biological media and living
and compartmentalized environment of
cells, the difficulties in finding a right
balance between stability and reactivity
of the metal complexes, and unavoidable
toxicity problems. However, there are
already an important number of results
ruthenium analogues under similar condi-
tions in active transfer-hydrogenation pro-
cesses, reporting the first example asym-
metric transfer hydrogenation of pyruvate,
with a high enantioselectivity in both aque-
ous and cellular media.[80]
The group of Winssinger has reported
in cellulo protein labeling with a Ru(ii)
polypyridyl-conjugate for luminescence
imaging and bioorthogonal photocataly-
sis. Specifically they achieved the photo-
reduction of p-azidobenzyl in biological
settings.[81] The same group also pub-
lished a nucleic-acid templated chemical
reaction in a live vertebrate using this type
of photoreactive Ru(ii) polypyridyl com-
plexes.[82]
4.2 Iridium
The biological uses of iridium organo-
metallic complexes have been mainly cen-
tered on their photophysical properties, as
imaging agents, rather than in catalysis.
The group of Sadler et al. also pioneered
interesting studies on the viability of us-
ing organoiridium complexes as catalytic
drugs inside cells to modulate the cellular
redox balance.[78,79,83–85]
In 2017 L. H. Do and coworkers de-
scribed iridium complexes capable of trig-
gering the reduction of exogenous alde-
hydes through hydride transfer processes
mediated by NADH, in the presence of
living cells.[86] This bioorthogonal reduc-
tion was also studied with substrates such
as BODIPY-CHO, which upon reduc-
tion to its alcoholic form BODIPY-OH
experiences a change in the intensity of
the fluorescence emission that can be de-
tected by fluorescence microscopy (Fig.
8).[87] Among the iridium catalysts used
in this study (J–L, Fig. 8) the one bear-
ing a pentametylcyclopendienyl ligand
and a chelating ligand like N-phenyl-2-
pyridinecarboxamidate (J) provided the
best results.[87]
4.3 Iron
The application of iron complexes to
promote non-natural intracellular trans-
formations with exogenous substrates
has been very limited to date. Indeed, to
the best of our knowledge, there is only
one report in this topic, consisting on the
use of the iron(iii) complex [Fe(TPP)]Cl
(N) to promote the reduction of the
Rhodamine-bisazide to Rhodamine 110
(Scheme 11).[88]
5. Conclusions and Closing
Remarks
Achieving organometallic catalytic
reactions of exogenous substrates in bio-
logical settings is an enormous challenge
owing to the hostile aqueous, crowded
Fig. 8. BODPY activation mediated by Ir(iii) promoted reduction. a) Representation of the BODIPY-
CHO reduction to BODIPY-OH promoted by Ir(iii) catalysts J–L; b) imaging of NIH-3T3 cells treated
with i) BODIPY-CHO (30 µM), ii) BODIPY-OH (30 µM), iii) BODIPY-CHO (30 µM)/J (20 µM), iv)
BODIPY-CHO (30 µM)/L (10 µM), v) BODIPY-CHO (30 µM)/IrCl3 (20 µM), and vi) BODIPY-CHO (30
µM)/J (20 µM)/sodium pyruvate (10 mM). Sodium pyruvate was used to slow down the production
of NADH which inhibited the hydride transfer from NADH to BODIPY-OH. Adapted by permission
from ref. [87]. Copyright 2017, Wiley-VCH.
Scheme 11. Azide reduction promoted by Fe-porphyrin-derived complex. a) Fe-porphyrin-derived
complex M used for the reduction reaction; and b) iron-catalyzed reduction of the bis-azide-Rho-
damine to generate the fluorescent Rhodamine 110.[88]
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